1. Referans1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
2. Referans 2 Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer. The Lancet Oncology. 2017;18(6):e307.
3. Referans 3 Lv X, Zhang L, Huang R, Song W. A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer. International journal of clinical and experimental medicine. 2015;8(10):19030.
4. Referans 4 Zhang X-y, Zhang P-y. Gastric cancer: somatic genetics as a guide to therapy. Journal of Medical Genetics. 2017;54(5):305-12.
5. Referans 5 Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. The lancet oncology. 2013;14(6):490-9.